How Can Oncology Trials Be Decentralized?

October 27, 2021 PAO-10-21-CL-16

On this episode of the PPD® podcast Oncology Imperatives, Dr. Dave Frakes, Vice President and Global Medical Officer for PPD Biotech, is joined by Simon Coggins, Vice President and Digital Solutions Lead for PPD’s hematology and oncology therapeutic unit, Mariah Baltezegar, Vice President of Peri- and Post-Approval Study Innovation, and Tim Rich, Vice President of Consulting, Innovation, and Strategy for PPD Digital, to discuss the current state of oncology clinical trials in the wake of COVID-19, patient-centric concerns, and the evolution of decentralized oncology clinical trials.

How Can Oncology Trials Be Decentralized?

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With more than 30,000 professionals worldwide, PPD has conducted clinical trials in more than 100 countries to help customers deliver life-changing therapies to improve health. We apply innovative technologies, therapeutic expertise and a firm commitment to quality to bend the cost and time curve of drug development and optimize value. For more information, visit www.ppd.com.

Q: